Lorus Therapeutics Announces FDA Approval to Initiate Phase I Clinical Trial for
First-in-Class Cancer Drug LOR-253
TORONTO, CANADA, July 19, 2010 - Lorus Therapeutics Inc. (TSX: LOR; OTCBB: LRUSF)
(“Lorus”) , a biopharmaceutical company specializing in the discovery and development of
pharmaceutical products and technologies for the management of cancer, today announced the
approval of the Investigational New Drug (IND) application for its anticancer drug candidate LOR-
253 by the U.S. Food & Drug Administration (FDA).
Based on the approval of the IND by the FDA, Lorus plans to proceed with a first-in-man Phase I
dose escalation trial with LOR-253 in advanced or metastatic solid tumors. The trial will assess the
safety profile, tolerability, and antitumor activity of LOR-253 in cancer patients, as well as
pharmacokinetic and pharmacodynamic properties of LOR-253. The Phase I trial will be conducted
at Memorial Sloan-Kettering Cancer Center in New York, NY.
LOR-253 represents a new class of anticancer agent, which we believe may offer a competitive
advantage over classical drugs. LOR-253 represents the first molecule among Lorus’ portfolio of
compounds with distinct and rational profiles selective for these targets. The drug has shown
selective and potent antitumor activity in preclinical investigations with a variety of human cancers,
including colon cancer and non-small cell lung cancer, and has demonstrated an excellent
therapeutic window due to its low toxicity. LOR-253 is a first-in-class small molecule that has been
optimized to inhibit a novel cancer target Metal-Responsive Transcription Factor 1 (MTF-1). MTF-1
is overexpressed in selective cancer indications and its downregulation by LOR-253 results in
induction of the novel tumor suppressor called Krüppel-like factor 4 (KLF-4), leading to the
downregulation of cyclin D1, an important regulator of cell cycle progression and cell proliferation.
MTF-1 downregulation also res